Teva Pharmaceutical Industries Ltd. — Director's Dealing 2024

May 15, 2024

	FORM 4				OMB APPROVAL
Instruction 1(b). Instruction 10. (Print or Type Responses)	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB Number: 3235-0287 Estimated average burden hours per response 0.5
1. Name and Address of Reporting Person * Conway Vikki L.			2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ]	5. Relationship of Reporting Person(s) to Issuer _____ Director	(Check all applicable)
(Last) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/13/2024	_ 10% Owner X __ Officer (give title below) _____ Other (specify below) See "Remarks"
	(Street)		4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
Tel Aviv, L3 6944020				_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City)	(State)	(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month /Day/Year)	2A. Deemed Execution Date, if any (Month/Day /Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	7. Nature of Indirect Beneficial
			Code	V	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Ordinary Shares (1)	05/13/2024		S		15,219	D	\$ 16.7427 (2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable Expiration Date			Title Amount or Number of Shares		Owned Following Reported Transaction (s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.74 to \$16.76, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Acting Head of Global Human Resources

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Vikki L. Conway 05/15/2024

Signature of Reporting Person ** Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.